Tricyclic inhibitors of kinases

A compound of formula (I):

• wherein
• X is N;
• Y is CR2;
• Z is O;
• R2 is H or C1-6-alkyl;
• R3 is aryl, wherein the aryl is optionally substituted with one or more substituents selected from the group consisting of C1-6-alkyl, C1-6-haloalkyl, C2-6-alkenyl, heterocycloalkyl, aryl, heteroaryl, halogen, oxo, cyano, nitro, —ORd, —C(O)Rd, —C(O)ORd, —OC(O)Rd, —SRd, —S(O)Rd, —SO2Rd, —NReRf, —NHC(O)Re, —NHC(O)NHRe, —NHC(O)ORe, —NHSO2Rd, —C(O)NHRe, and —SO2NHNRe;
• R4 is
• phenyl, which is optionally substituted with one or more R5;
• or
• R5, at each occurrence, is independently CN, NO2, halo, C1-6-alkyl, ORg, SRg, C(O)Rg, C(O)NRhRi, C(O)ORg, NRhRi, NRhC(O)Rg, S(O)2Rg, NRhS(O)2Rg, S(O)2NRhRi, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl, wherein the C1-6-alkyl is optionally substituted with one or more substituents selected from the group consisting of CN, halo, hydroxy, S(O)2NH(C1-6-alkyl), C1-6-alkoxy, heterocycloalkyl, cycloalkyl, heteroaryl, aryl, —NH2, —NHC1-6-alkyl, and —N(C1-6-alkyl)2;
• wherein the aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, alone or as part of another moiety, is optionally substituted with one or more R7;
• R7, at each occurrence, is independently CN, NO2, halo, oxo, C1-6 alkyl, aryl, C3-8 cycloalkyl, heteroaryl, heterocycloalkyl, ORm, SRm, C(O)Rm, C(O)NRnRo, C(O)ORm, OC(O)Rm, OC(O)NRnRo, NRnRo, NRnC(O)Rm, S(O)Rm, S(O)NRnRo, S(O)2Rm, NRnS(O)2Rm, or S(O)2NRnRo, wherein the C1-6-alkyl is optionally substituted with one or more substituents selected from the group consisting of CN, halo, hydroxy, C1-6-alkoxy, heterocycloalkyl, cycloalkyl, aryl, heteroaryl, —NH2, —NHC1-6-alkyl, and —N(C1-6-alkyl)2, wherein the aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl, alone or as part of another moiety, are optionally substituted with one, two or three substituents independently selected from CN, halo, and C1-6 alkyl;
• Rd, at each occurrence, is independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
• Re and Rf, at each occurrence, are independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
• Rg, at each occurrence, is independently selected from the group consisting of H, C1-6 alkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
• wherein the C1-6-alkyl is optionally substituted with one or more substituents selected from the group consisting of CN, halo, hydroxy, C1-6-alkoxy, heterocycloalkyl, —NH2, —NHC1-6-alkyl, and —N(C1-6-alkyl)2, and wherein the aryl, C3-8 cycloalkyl, heteroaryl, or heterocycloalkyl, alone or as part of another moiety, is optionally substituted with one or more substituents selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, —C(O) C1-6-alkyl, —S(O)2C1-6-alkyl, —NH2, —NH(C1-6-alkyl), —N(C1-6-alkyl)2, and —N(C1-6-alkyl)(C3-8-cycloalkyl);
• Rh and Ri, at each occurrence, are independently selected from the group consisting of H, C1-6 alkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
• wherein the C1-6-alkyl is optionally substituted with one or more substituents selected from the group consisting of CN, halo, hydroxy, C1-6-alkoxy, heterocycloalkyl, —NH2, —NHC1-6-alkyl, and —N(C1-6-alkyl)2, and wherein the aryl, C3-8 cycloalkyl, heteroaryl, or heterocycloalkyl, alone or as part of another moiety, is optionally substituted with one or more substituents selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, —C(O)C1-6-alkyl, —S(O)2C1-6-alkyl, —NH2, —NH(C1-6-alkyl), N(C1-6-alkyl)2, and —N(C1-6-alkyl)(C3-8-cycloalkyl);
• Rm, at each occurrence, is independently selected from the group consisting of H, C1-6 alkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
• wherein the C1-6-alkyl is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C1-6-alkoxy, —NH2, —NHC1-6-alkyl, and —N(C1-6-alkyl)2, and wherein the aryl, C3-8 cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with one or more substituents selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, —NH2, —NH(C1-6-alkyl), and N(C1-6-alkyl)2;
• Rn and Ro, at each occurrence, are independently selected from the group consisting of H, C1-6 alkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
• wherein the C1-6-alkyl is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, C1-6-alkoxy, —NH2, —NHC1-6-alkyl, and —N(C1-6-alkyl)2, and wherein the aryl, C3-8 cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with one or more substituents selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, —NH2, —NH(C1-6-alkyl), and N(C1-6-alkyl)2;
• or a pharmaceutically acceptable salt or solvate thereof.